2022
Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation
Wei Y, Wei C, Chen L, Liu N, Ou Q, Yin J, Pang J, Fang Z, Wu X, Wang X, Mu D, Shao Y, Yu J, Yuan S. Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation. Cancer Research And Treatment 2022, 54: 1209-1218. PMID: 35038823, PMCID: PMC9582489, DOI: 10.4143/crt.2021.963.Peer-Reviewed Original ResearchConceptsDisease-free survivalAdvanced cervical cancerAdvanced cervical cancer patientsCervical cancer patientsTumor biopsy samplesCervical cancerNeoadjuvant chemoradiationPathologic responseCancer patientsKEAP1 mutationsHigh tumor mutation burdenNeoadjuvant chemoradiation treatmentPoor pathologic responseEarly disease recurrenceTumor mutation burdenGenetic alterationsDNA damage repair genesOperability rateChemoradiation treatmentNeoadjuvant therapyNeoadjuvant treatmentRadical hysterectomyCancer Genome AtlasDisease recurrenceDisease relapse
2021
Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors
Huo K, Notsuda H, Fang Z, Liu N, Gebregiworgis T, Li Q, Pham N, Li M, Liu N, Shepherd F, Marshall C, Ikura M, Moghal N, Tsao M. Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. Journal Of Thoracic Oncology 2021, 17: 277-288. PMID: 34648945, DOI: 10.1016/j.jtho.2021.09.008.Peer-Reviewed Original ResearchConceptsEGFR tyrosine kinase inhibitorsTyrosine kinase inhibitorsLung cancerBRAF mutationsNon-small cell lung cancerNon-V600 BRAF mutationsPatient-derived xenograft modelsKinase inhibitorsCell lung cancerEGFR-TKI gefitinibSingle-agent vemurafenibV600E BRAF mutationRNA knockdownCell linesExpression of BRAFOff-target inhibitionCombination dabrafenibTKI gefitinibTargeted therapyLung adenocarcinomaXenograft modelEGFR kinase inhibitorsPatientsOncogenic driversBRAF